Release date: 26 June 2012
Promoter – Financial Intermediary
MERCK KGAALocation
Description
The project will finance the promoter’s research and development (R&D) expenses for the development of a new cancer treatment. It concerns the clinical programme of a cancer vaccine for indications such as NSCLC (non-small-cell lung cancer), which is the major indication currently investigated, as well as trials for colorectal- , prostate- and breast cancer indications.
Objectives
It is the objective of this new cancer vaccine to stimulate the body's immune system to identify and destroy cancer cells.
Sector(s)
Proposed EIB finance (Approximate amount)
EUR 200 million
Total cost (Approximate amount)
EUR 625 million
Environmental aspects
R&D activities included in the project will not materially change current R&D practice and will be carried out within existing facilities making use of existing laboratories, pilot plants, clinical centres, etc. An Environmental Impact Assessment (EIA) by a competent authority according to the Directive 85/337/EEC, amended by Directives 97/11/EC and 2003/35/EC should not be required.
Procurement
The promoter is a private company not operating in the utilities sector, and is thus not covered by EU Directives on procurement.
Status
Signed - 16/07/2013
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).